Adverse reactions to dietary supplements containing red yeast rice: assessment of cases from the Italian surveillance system

British Journal of Clinical Pharmacology

Volumn 83, Issue 4, 2017, Pages 894-908

  Mazzanti, Gabriela ^a   Moro, Paola Angela ^b   Raschi, Emanuel ^c   Da Cas, Roberto ^d   Menniti Ippolito, Francesca ^d  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b Niguarda Ca' Grande Hospital   (Italy)

^c UNIVERSITY OF BOLOGNA   (Italy)

^d ISTITUTO SUPERIORE DI SANITÀ   (Italy)

Author keywords

adverse reactions; dietary supplements; monacolin; Monascus purpureus; red yeast rice; statins

Indexed keywords

ALPHA TOCOPHEROL; ASTAXANTHIN; BERBERIS ARISTATA DRY EXTRACT; CARVEDILOL; CHOLESTIN; CREATINE KINASE; CYANOCOBALAMIN; FISH OIL; FOLIC ACID; GLYCERYL TRINITRATE; HERBACEOUS AGENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LANSOPRAZOLE; MEVINOLIN; MIANSERIN; NATURAL PRODUCT; PLANT EXTRACT; POLICOSANOL; PROPOLIS; PYRIDOXINE; RAMIPRIL; RESVERATROL; ROYAL JELLY; SALMETEROL; SNAKE VENOM ANTISERUM; THEOPHYLLINE; TIOTROPIUM BROMIDE; TORASEMIDE; UBIDECARENONE; UNCLASSIFIED DRUG; UNINDEXED DRUG; BIOLOGICAL PRODUCT;

ABDOMINAL PAIN; ADULT; ADVERSE DRUG REACTION; AGED; ARTICLE; ASSESSMENT OF HUMANS; BERBERIS ARISTATA; CAUSALITY; CIOMS RUCAM SCORE; CLINICAL EVALUATION; CONNECTIVE TISSUE DISEASE; CONTROLLED STUDY; CREATINE KINASE BLOOD LEVEL; DATA COLLECTION METHOD; DIETARY SUPPLEMENT; DIZZINESS; DRUG ERUPTION; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; DRUG TOLERABILITY; EDEMA; FEMALE; GASTROINTESTINAL DISEASE; GASTROINTESTINAL SYMPTOM; HEPATITIS; HEPATOBILIARY DISEASE; HERPES SIMPLEX; HOSPITALIZATION; HUMAN; HYPERCHOLESTEROLEMIA; ITALY; LIVER INJURY; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MUSCLE INJURY; MUSCLE SPASM; MUSCULOSKELETAL DISEASE; MYALGIA; MYOPATHY; NAUSEA; PEMPHIGUS VULGARIS; PHARMACOGNOSY; PRIORITY JOURNAL; PRURITUS; RHABDOMYOLYSIS; RISK ASSESSMENT; SCORING SYSTEM; SIDE EFFECT; SKIN DISEASE; SKIN MANIFESTATION; STEATOSIS; TACHYCARDIA; TEA; THORAX PAIN; URTICARIA; VERTIGO; VERY ELDERLY; VOMITING; WORLD HEALTH ORGANIZATION; EPIDEMIOLOGY; FACTUAL DATABASE; STATISTICS AND NUMERICAL DATA;

ADULT; ADVERSE DRUG REACTION REPORTING SYSTEMS; AGED; AGED, 80 AND OVER; BIOLOGICAL PRODUCTS; DATABASES, FACTUAL; DIETARY SUPPLEMENTS; FEMALE; HOSPITALIZATION; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; ITALY; MALE; MIDDLE AGED;

EID: 85010216408     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/bcp.13171     Document Type: Article

References (64)

1. Southan C, Sharman JL, Benson HE, Faccenda E, Pawson AJ, Alexander SP, et al. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. Nucl Acids Res 2016; 44: D1054–D1068.
2. Alexander SPH, Fabbro D, Kelly E, Marrion N, Peters JA, Benson HE, et al. The Concise Guide to PHARMACOLOGY 2015/16: Enzymes. Br J Pharmacol 2015; 172: 6024–6109.
3. Geller AI, Shehab N, Weidle NJ, Lovegrove MC, Wolpert BJ, Timbo BB, et al. Emergency department visits for adverse events related to dietary supplements. N Engl J Med 2015; 373: 1531–1540.
4. Menniti-Ippolito F, Mazzanti G, Santuccio C, Moro PA, Calapai G, Firenzuoli F, et al. Surveillance of suspected adverse reactions to natural health products in Italy. Pharmacoepidemiol Drug Saf 2008; 17: 626–635.
5. Lee JY, Jun SA, Hong SS, Ahn YC, Lee DS, Son CG. Systematic review of adverse effects from herbal drugs reported in randomized controlled trials. Phytother Res 2016; 30: 1412–1419.
6. Brown AC. Liver toxicity related to herbs and dietary supplements: Online table of case reports. Part 3 of 6. Food Chem Toxicol 2016. doi:10.1016/j.fct.2016.07.001.
7. Di Lorenzo C, Ceschi A, Kupferschmidt H, Lüde S, De Souza Nascimento E, Dos Santos A, et al. Adverse effects of plant food supplements and botanical preparations: a systematic review with critical evaluation of causality. Br J Clin Pharmacol 2015; 79: 578–592.
8. Ma J, Li Y, Ye Q, Li J, Hua Y, Ju D, et al. Constituents of red yeast rice, a traditional Chinese food and medicine. J Agric Food Chem 2000; 48: 5220–5225.
9. Becker DJ, Gordon RY, Halbert SC, French B, Morris PB, Rader DJ. Red yeast rice for dyslipidemia in statin-intolerant patients: a randomized trial. Ann Intern Med 2009; 150: 830–839.
10. Venero CV, Venero JV, Wortham DC, Thompson PD. Lipid-lowering efficacy of red yeast rice in a population intolerant to statins. Am J Cardiol 2010; 105: 664–666.
11. Moriarty PM, Roth EM, Karns A, Ye P, Zhao SP, Liao Y, et al. Effects of Xuezhikang in patients with dyslipidemia: a multicenter, randomized, placebo-controlled study. J Clin Lipidol 2014; 8: 568–575.
12. Heber D, Yip I, Ashley JM, Elashoff DA, Elashoff RM, Go VL. Cholesterol-lowering effects of a proprietary Chinese red-yeast-rice dietary supplement. Am J Clin Nutr 1999; 69: 231–236.
13. Gonnelli S, Caffarelli C, Stolakis K, Cuda C, Giordano N, Nuti R. Efficacy and tolerability of a nutraceutical combination (red yeast rice, policosanols, and berberine) in patients with low-moderate risk hypercholesterolemia: a double-blind, placebo-controlled study. Curr Ther Res Clin Exp 2014; 77: 1–6.
14. Halbert SC, French B, Gordon RY, Farrar JT, Schmitz K, Morris PB, et al. Tolerability of red yeast rice (2, 400 mg twice daily) versus pravastatin (20 mg twice daily) in patients with previous statin intolerance. Am J Cardiol 2010; 105: 198–204.
15. Marazzi G, Pelliccia F, Campolongo G, Quattrino S, Cacciotti L, Volterrani M, et al. Usefulness of nutraceuticals (Armolipid plus) versus ezetimibe and combination in statin-intolerant patients with dyslipidemia with coronary heart disease. Am J Cardiol 2015; 116: 1798–1801.
16. Ong YC, Aziz Z. Systematic review of red yeast rice compared with simvastatin in dyslipidaemia. J Clin Pharm Ther 2016; 41: 170–179.
17. Childress L, Gay A, Zargar A, Ito MK. Review of red yeast rice content and current Food and Drug Administration oversight. J Clin Lipidol 2013; 7: 117–122.
18. Wild D, Toth G, Humpf HU. New monascus metabolite isolated from red yeast rice (angkak, red koji). J Agric Food Chem 2002; 50: 3999–4002.
19. Flajs D, Peraica M. Toxicological properties of citrinin. Arh Hig Rada Toksikol 2009; 60: 457–464.
20. Gordon RY, Becker DJ. The role of red yeast rice for the physician. Curr Atheroscler Rep 2011; 13: 73–80.
21. Burke FM. Red yeast rice for the treatment of dyslipidemia. Curr Atheroscler Rep 2015; 17: 495.
22. Gerards MC, Terlou RJ, Yu H, Koks CH, Gerdes VE. Traditional Chinese lipid-lowering agent red yeast rice results in significant LDL reduction but safety is uncertain – a systematic review and meta-analysis. Atherosclerosis 2015; 240: 415–423.
23. Lapi F, Gallo E, Bernasconi S, Vietri M, Menniti-Ippolito F, Raschetti R, et al. Myopathies associated with red yeast rice and liquorice: spontaneous reports from the Italian Surveillance System of Natural Health Products. Br J Clin Pharmacol 2008; 66: 572–574.
24. Grieco A, Miele L, Pompili M, Biolato M, Vecchio FM, Grattagliano I, et al. Acute hepatitis caused by a natural lipid-lowering product: when ‘alternative’ medicine is no ‘alternative’ at all. J Hepatol 2009; 50: 1273–1277.
25. Philibert C, Bres V, Jean-Pastor MJ, Guy C, Lebrun-Vignes B, Robin P, et al. Red yeast rice induced muscular injuries: analysis of French pharmacovigilance database and literature review. Therapie 2015. doi:10.2515/therapie/2015053.
26. Smith DJ, Olive KE. Chinese red rice-induced myopathy. South Med J 2003; 96: 1265–1267.
27. Mueller PS. Symptomatic myopathy due to red yeast rice. Ann Intern Med 2006; 145: 474–475.
28. Vercelli L, Mongini T, Olivero N, Rodolico C, Musumeci O, Palmucci L. Chinese red rice depletes muscle coenzyme Q10 and maintains muscle damage after discontinuation of statin treatment. J Am Geriatr Soc 2006; 54: 718–720.
29. Polsani VR, Jones PH, Ballantyne CM, Nambi V. A case report of myopathy from consumption of red yeast rice. J Clin Lipidol 2008; 2: 60–62.
30. Opinion of the French Agency for Food, Environmental and Occupational Health & Safety (ANSES) on the risks associated with the presence of ‘red yeast rice’ in food supplements. February 14, 2014. Available at https://www.anses.fr/en/system/files/NUT2012sa0228EN.pdf (last accessed 21 September 2016).
31. Aronson JK, Hauben M. Anecdotes that provide definitive evidence. BMJ 2006; 333: 1267–1269.
32. World Health Organization Geneva 2004. WHO guidelines on safety monitoring of herbal medicines in pharmacovigilance systems. Available at http://apps.who.int/medicinedocs/documents/s7148e/s7148e.pdf (last accessed 29 December 2015).
33. The Uppsala Monitoring Center. The use of the WHO-UMC system for standardised case causality assessment. Available at http://who-umc.org/Graphics/24734.pdf (last accessed 29 December 2015).
34. Teschke R, Frenzel C, Glass X, Schulze J, Eickhoff A. Herbal hepatotoxicity: a critical review. Br J Clin Pharmacol 2013; 75: 630–636.
35. Edwards IR, Aronson JK. Adverse drug reactions: definitions, diagnosis, and management. Lancet 2000; 356: 1255–1259.
36. Wilson AD, Howell C, Waring WS. Venlafaxine ingestion is associated with rhabdomyolysis in adults: a case series. J Toxicol Sci 2007; 32: 97–101.
37. Huang SS, Yang HY, Lin YC, Chan CH. Low-dose venlafaxine-induced severe rhabdomyolysis: a case report. Gen Hosp Psychiatry 2012; 34: 436–437.
38. Thomson Micromedex® Medication, Disease and Toxicology Management. Available at http://www.micromedexsolutions.com/micromedex2/librarian (last accessed 29 December 2015).
39. Aithal GP, Watkins PB, Andrade RJ, Larrey D, Molokhia M, Takikawa H, et al. Case definition and phenotype standardization in drug-induced liver injury. Clin Pharmacol Ther 2011; 89: 806–815.
40. Danan G, Benichou C. Causality assessment of adverse reactions to drugs – I. A novel method based on the conclusions of international consensus meetings: application to drug-induced liver injuries. J Clin Epidemiol 1993; 46: 1323–1330.
41. Benichou C, Danan G, Flahault A. Causality assessment of adverse reactions to drugs – II. An original model for validation of drug causality assessment methods: case reports with positive rechallenge. J Clin Epidemiol 1993; 46: 1331–1336.
42. Thestrup-Pedersen K. Adverse reactions in the skin from anti-hypertensive drugs. Dan Med Bull 1987; 34 (Suppl 1): 3–5.
43. Gonzalez P, Soriano V, Lopez P, Niveiro E. Anaphylaxis to proton pump inhibitors. Allergol Immunopathol (Madr) 2002; 30: 342–343.
44. Avancini J, Maragno L, Santi CG, Criado PR. Drug reaction with eosinophilia and systemic symptoms/drug-induced hypersensitivity syndrome: clinical features of 27 patients. Clin Exp Dermatol 2015; 40: 851–859.
45. Descamps V, Ranger-Rogez S. DRESS syndrome. Joint Bone Spine 2014; 81: 15–21.
46. Gressier L, Pruvost-Balland C, Dubertret L, Viguier M. Atorvastatin-induced drug reaction with eosinophilia and systemic symptoms (DRESS). Ann Dermatol Venereol 2009; 136: 50–53.
47. Bourneau-Martin D, Leclech C, Jamet A, Drablier G, Trenque T, Juengel K, et al. Omeprazole-induced drug reaction with eosinophilia and systemic symptoms (DRESS). Eur J Dermatol 2014; 24: 413–415.
48. Naci H, Brugts J, Ades T. Comparative tolerability and harms of individual statins: a study-level network meta-analysis of 246 955 participants from 135 randomized, controlled trials. Circ Cardiovasc Qual Outcomes 2013; 6: 390–399.
49. Bruguera M, Joya P, Rodes J. Hepatitis associated with treatment with lovastatin. Presentation of 2 cases. Gastroenterol Hepatol 1998; 21: 127–128.
50. Bjornsson E, Jacobsen EI, Kalaitzakis E. Hepatotoxicity associated with statins: reports of idiosyncratic liver injury post-marketing. J Hepatol 2012; 56: 374–380.
51. Perdices EV, Medina-Caliz I, Hernando S, Ortega A, Martin-Ocana F, Navarro JM, et al. Hepatotoxicity associated with statin use: analysis of the cases included in the Spanish Hepatotoxicity Registry. Rev Esp Enferm Dig 2014; 106: 246–254.
52. Goldberg I, Isman G, Shirazi I, Brenner S. Interferon-gamma (INF-gamma) release test can detect cutaneous adverse effects to statins. Int J Dermatol 2009; 48: 1370–1375.
53. Adams AE, Bobrove AM, Gilliam AC. Statins and ‘chameleon-like’ cutaneous eruptions: simvastatin-induced acral cutaneous vesiculobullous and pustular eruption in a 70-year-old man. J Cutan Med Surg 2010; 14: 207–211.
54. Tan J, Pretorius CF, Flanagan PV, Pais A. Adverse drug reaction: rosuvastatin as a cause for ischaemic colitis in a 64-year-old woman. BMJ Case Rep 2012; 2012.
55. Wilinski J, Dabrowski M. Safety and tolerability of the use of atorvastatin 40 mg in common daily practice in short-term observation in 3227 patients. Przegl Lek 2013; 70: 373–376.
56. Marques-Vidal P, Pecoud A, Hayoz D, Paccaud F, Mooser V, Waeber G, et al. Prevalence and characteristics of vitamin or dietary supplement users in Lausanne, Switzerland: the CoLaus study. Eur J Clin Nutr 2009; 63: 273–281.
57. Schwab S, Heier M, Schneider A, Fischer B, Huth C, Peters A, et al. The use of dietary supplements among older persons in southern Germany – results from the KORA-age study. J Nutr Health Aging 2014; 18: 510–519.
58. Barnes J, Mills SY, Abbot NC, Willoughby M, Ernst E. Different standards for reporting ADRs to herbal remedies and conventional OTC medicines: face-to-face interviews with 515 users of herbal remedies. Br J Clin Pharmacol 1998; 45: 496–500.
59. Barnes J. Pharmacovigilance of herbal medicines: a UK perspective. Drug Saf 2003; 26: 829–851.
60. Prasad GV, Wong T, Meliton G, Bhaloo S. Rhabdomyolysis due to red yeast rice (Monascus purpureus) in a renal transplant recipient. Transplantation 2002; 74: 1200–1201.
61. Roselle H, Ekatan A, Tzeng J, Sapienza M, Kocher J. Symptomatic hepatitis associated with the use of herbal red yeast rice. Ann Intern Med 2008; 149: 516–517.
62. EFSA Panel on Dietetic Products, Nutrition and Allergies NDA. Scientific opinion on the substantiation of health claims related to monacolin K from red yeast rice and maintenance of normal blood LDL-cholesterol concentrations (ID 1648, 1700) pursuant to Article 13(1) of Regulation (EC) No 1924/2006. EFSA J 2011; 9: 2304.
63. Gordon RY, Cooperman T, Obermeyer W, Becker DJ. Marked variability of monacolin levels in commercial red yeast rice products: buyer beware! Arch Intern Med 2010; 170: 1722–1727.
64. Avula B, Cohen PA, Wang YH, Sagi S, Feng W, Wang M, et al. Chemical profiling and quantification of monacolins and citrinin in red yeast rice commercial raw materials and dietary supplements using liquid chromatography-accurate QToF mass spectrometry: Chemometrics application. J Pharm Biomed Anal 2014; 100: 243–253.